266 related articles for article (PubMed ID: 35343853)
1. The use of patient-reported outcome measures to classify type 1 and 2 systemic lupus erythematosus activity.
Eudy AM; Reeve BB; Coles T; Lin L; Rogers JL; Pisetsky DS; Criscione-Schreiber LG; Doss J; Sadun R; Sun K; Clowse ME
Lupus; 2022 May; 31(6):697-705. PubMed ID: 35343853
[TBL] [Abstract][Full Text] [Related]
2. Using Clinical Characteristics and Patient-Reported Outcome Measures to Categorize Systemic Lupus Erythematosus Subtypes.
Rogers JL; Eudy AM; Pisetsky D; Criscione-Schreiber LG; Sun K; Doss J; Clowse MEB
Arthritis Care Res (Hoboken); 2021 Mar; 73(3):386-393. PubMed ID: 31909888
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Type 2 SLE symptoms in patients with a range of lupus nephritis activity.
Rogers JL; Clowse MEB; Pisetsky DS; Criscione-Schreiber LG; Sun K; Sadun RE; Maheswaranathan M; Burshell DR; Doss J; Eudy AM
Clin Rheumatol; 2024 Apr; 43(4):1319-1326. PubMed ID: 38409491
[TBL] [Abstract][Full Text] [Related]
4. Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study.
Sun K; Eudy AM; Harris N; Pisetsky DS; Criscione-Schreiber LG; Sadun RE; Doss J; Clowse MEB; Rogers JL
J Patient Rep Outcomes; 2023 Dec; 7(1):136. PubMed ID: 38127169
[TBL] [Abstract][Full Text] [Related]
5. Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms.
Clowse MEB; Rogers JL; Coles T; Pisetsky DS; Criscione-Schreiber LG; Burshell D; Doss J; Sadun RE; Sun K; Maheswaranathan M; Eudy AM
Lupus Sci Med; 2023 Dec; 10(2):. PubMed ID: 38105242
[TBL] [Abstract][Full Text] [Related]
6. Translation, cultural adaptation and validation of the Systemic Lupus Erythematosus Activity Questionnaire (SLAQ) in a cohort of Italian systemic lupus erythematosus patients.
Tani C; Vagelli R; Stagnaro C; Carli L; Lorenzoni V; Drago F; Doherty W; McSorley MR; Marconcini L; Della Rossa A; Turchetti G; Mosca M
Lupus; 2018 Sep; 27(10):1735-1741. PubMed ID: 30045666
[TBL] [Abstract][Full Text] [Related]
7. Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus.
Mertz P; Piga M; Chessa E; Amoura Z; Voll RE; Schwarting A; Maurier F; Blaison G; Bonnotte B; Poindron V; Fiehn C; Lorenz HM; Korganow AS; Sibilia J; Martin T; Arnaud L
RMD Open; 2022 Sep; 8(2):. PubMed ID: 36123013
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study.
Uhrenholt L; Høstgaard S; Pedersen JF; Christensen R; Dreyer L; Leffers HCB; Taylor PC; Strand V; Jacobsen S; Voss A; Gregersen JW; Kristensen S
Lupus; 2021 Nov; 30(13):2124-2134. PubMed ID: 34719299
[TBL] [Abstract][Full Text] [Related]
9. Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN).
Williams-Hall R; Berry P; Williamson N; Barclay M; Roberts A; Gater A; Tolley C; Bradley H; Ward A; Hsia E; Zuraw Q; DeLong P; Touma Z; Strand V
Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 36007978
[TBL] [Abstract][Full Text] [Related]
10. Quantitative data for care of patients with systemic lupus erythematosus in usual clinical settings: a patient Multidimensional Health Assessment Questionnaire and physician estimate of noninflammatory symptoms.
Askanase AD; Castrejón I; Pincus T
J Rheumatol; 2011 Jul; 38(7):1309-16. PubMed ID: 21459938
[TBL] [Abstract][Full Text] [Related]
11. Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity.
Svenungsson E; Gunnarsson I; Illescas-Bäckelin V; Trysberg E; Jönsen A; Leonard D; Sjöwall C; Pettersson S
Lupus Sci Med; 2021 May; 8(1):. PubMed ID: 33972457
[TBL] [Abstract][Full Text] [Related]
12. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE.
Askanase AD; Tang W; Zuraw Q; Gordon R; Brotherton B; Merrill JT
Lupus Sci Med; 2023 Apr; 10(1):. PubMed ID: 37012059
[TBL] [Abstract][Full Text] [Related]
14. Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms.
Eudy AM; Rogers JL; Corneli A; McKenna K; Maheswaranathan M; Pisetsky DS; Criscione-Schreiber LG; Doss J; Sadun RE; Sun K; Clowse MEB
Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 36927502
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort.
Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Zeña-Huancas P; Elera-Fitzcarrald C; Garcia-Hirsh S; Gil L; Pastor-Asurza CA; Rodriguez-Bellido Z; Merrill J; Askanase AD; Alarcon G; Perich-Campos RA
Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33046557
[TBL] [Abstract][Full Text] [Related]
16. Associations between physicians' global assessment of disease activity and patient-reported outcomes in patients with systemic lupus erythematosus: A longitudinal study.
Louthrenoo W; Kasitanon N; Morand E; Kandane-Rathnayake R
Lupus; 2021 Sep; 30(10):1586-1595. PubMed ID: 34192957
[TBL] [Abstract][Full Text] [Related]
17. Categorization of patients with systemic lupus erythematosus using disease activity, patient-reported outcomes, and transcriptomic signatures.
Arcani R; Jouve E; Chiche L; Jourde-Chiche N
Clin Rheumatol; 2023 Jun; 42(6):1555-1563. PubMed ID: 36759402
[TBL] [Abstract][Full Text] [Related]
18. Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus.
Mok CC; Ding HH; Kharboutli M; Mohan C
Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1303-9. PubMed ID: 26749069
[TBL] [Abstract][Full Text] [Related]
19. Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS).
Chaigne B; Chizzolini C; Perneger T; Trendelenburg M; Huynh-Do U; Dayer E; Stoll T; von Kempis J; Ribi C;
BMC Immunol; 2017 Mar; 18(1):17. PubMed ID: 28351341
[TBL] [Abstract][Full Text] [Related]
20. Patient and Physician Perspectives of Systemic Lupus Erythematosus Flare: A Qualitative Study.
Rogers JL; Clowse MEB; McKenna K; Starling S; Swezey T; Molokwu N; Corneli A; Pisetsky DS; Sun K; Criscione-Schreiber LG; Sadun RE; Maheswaranathan M; Burshell D; Doss J; Eudy AM
J Rheumatol; 2024 May; 51(5):488-494. PubMed ID: 38101916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
